Dr. Anderson of the Peter MacCallum Cancer Center speaks about the plenary session on chronic lymphocytic leukemia (CLL) she delivered during the Eleventh Annual Meeting of the Society of Hematologic Oncology.
“The era of nonchemo[therapy]-based treatment for CLL is … truly here, and I think that has been an absolute breakthrough,” she said. “Now, we’ve just got to work out how we best sequence these great new classes of drugs that we have to get the best outcomes for our patients over the long term.”
The topic of her plenary session was emerging BCL2 inhibitors.
“That’s emblematic of what’s happening in CLL,” Dr. Anderson said. “We’re getting more and more fantastic new drugs.”
She also spoke about the need to identify which patients will benefit most from given therapies so clinicians can “select from a plethora of potential agents” to determine “the best one for this patient right now.”